Encompass Health (EHC)
(Real Time Quote from BATS)
$83.56 USD
+1.09 (1.32%)
Updated Apr 29, 2024 11:24 AM ET
2-Buy of 5 2
A Value A Growth C Momentum A VGM
Encompass Health (EHC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$91.00 | $101.00 | $83.00 | 10.34% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Encompass Health comes to $91.00. The forecasts range from a low of $83.00 to a high of $101.00. The average price target represents an increase of 10.34% from the last closing price of $82.47.
Analyst Price Targets (9 )
Broker Rating
Encompass Health currently has an average brokerage recommendation (ABR) of 1.10 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.10 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90% and 10% of all recommendations. A month ago, Strong Buy made up 90%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.10 | 1.10 | 1.10 | 1.30 | 1.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/25/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
2/9/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
2/8/2024 | Raymond James | John W Ransom | Strong Buy | Strong Buy |
2/7/2024 | William Blair | Jared Haase | Not Available | Strong Buy |
11/1/2023 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.10 |
ABR (Last week) | 1.10 |
# of Recs in ABR | 10 |
Average Target Price | $91.00 |
LT Growth Rate | 15.00% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 151 of 252 |
Current Quarter EPS Est: | 1.01 |